{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Fisher Exact","testedNonInferiority":false},{"ciPctValue":"95","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Fisher Exact","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"2.7","value":"0.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"1.8","value":"0.0"},{"groupId":"OG002","lowerLimit":"73.9","upperLimit":"85.4","value":"80.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"201"}],"units":"Participants"}],"description":"A patient was defined as having a testosterone surge if the testosterone level exceeded baseline by \\>=15% on any two days during the first two weeks of treatment (i.e. two of Study Days 1, 3, 7 and 14).","dispersionType":"95% Confidence Interval","groups":[{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.","id":"OG000","title":"Degarelix 240/160 mg"},{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.","id":"OG001","title":"Degarelix 240/80 mg"},{"description":"Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.","id":"OG002","title":"Leuprolide 7.5 mg"}],"paramType":"MEAN","populationDescription":"ITT population. If one or more of the testosterone values on Days 1, 3, 7 or 14 was missing, the last observation was carried forward.","reportingStatus":"POSTED","timeFrame":"2 weeks","title":"Percentage of Patients With Testosterone Surge During the First Two Weeks of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of patients"}